The Mesoblast Ltd (ASX: MSB) share price is in focus after the company reported Ryoncil® net revenue of US$36 million for the June quarter and US$115 million in its first full year since product launch.
Image source: Getty Images
What did Mesoblast report?
- Ryoncil® net revenue of US$36 million for the fourth quarter
- US$115 million in Ryoncil® net revenue for the first full year since FDA approval
- Net operating cash spend of US$43.8 million for FY26
- US$103 million cash on hand at 30 June 2026 (after extinguishing debt obligations)
- At least 300 patients treated in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain
What else do investors need to know?
Mesoblast is expanding Ryoncil® into new patient groups. Trials have commenced to extend its label from children to adults with steroid-refractory acute graft versus host disease (SR-aGvHD), a market expected to be three times larger. The company is also advancing trials for use in severe inflammatory conditions, including Duchenne muscular dystrophy.
The pivotal Phase 3 trial of rexlemestrocel-L met its target of over 300 chronic low back pain patients, with results to be followed over 12 months. In addition, Mesoblast received clearance to proceed with a registrational trial for Ryoncil® in children with Duchenne muscular dystrophy and filed for a biologic licence for rexlemestrocel-L in heart failure.
Mesoblast unveiled next-generation cell therapy strategies, securing a worldwide licence for chimeric antigen receptor (CAR) technology, aiming to develop new products for conditions such as ulcerative colitis, Crohn's disease, and lupus nephritis.
What did Mesoblast management say?
Mesoblast Chief Executive Dr. Silviu Itescu said:
We are very pleased with the continued momentum in uptake of Ryoncil® in children with life-threatening steroid-refractory acute GvHD across major U.S. pediatric centres, positioning the treatment well for use next in adults with this life-threatening disease. We will continue to build on the strong first full year of Ryoncil® revenue to ensure our judicious use of capital facilitates achievement of key inflexion points for our blockbuster products, including potential FDA approvals.
What's next for Mesoblast?
Mesoblast is focused on extending its lead product, Ryoncil®, into adult SR-aGvHD and other severe inflammatory conditions. The company expects up to 40 U.S. trial sites to enrol adults, representing approximately 60% of the annual U.S. bone marrow transplant population.
Looking forward, Mesoblast will follow patients in its chronic low back pain trial to collect safety and efficacy data, while progressing regulatory filings for both Ryoncil® and rexlemestrocel-L. Management has flagged ongoing innovation and new product opportunities through its CAR technology platform.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 16%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.
